Enliven Therapeutics (ELVN) Total Current Liabilities (2019 - 2026)

Enliven Therapeutics has disclosed Total Current Liabilities across 8 years of filings, most recently posting $11.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $11.5 million, down 17.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.79% YoY), and the FY2025 annual result was $16.6 million, up 4.1% from the prior year.
• Total Current Liabilities came in at $11.5 million for Q1 2026 at Enliven Therapeutics, down from $16.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.9 million in Q4 2023 to a low of $1.8 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $14.0 million (2025), against an average of $13.7 million.
• Across the five-year window, Total Current Liabilities slumped 74.71% in 2022 and jumped 564.41% in 2023, its largest moves.
• Enliven Therapeutics' Total Current Liabilities stood at $9.7 million in 2022, then soared by 166.54% to $25.9 million in 2023, then tumbled by 38.54% to $15.9 million in 2024, then advanced by 4.1% to $16.6 million in 2025, then sank by 30.67% to $11.5 million in 2026.
• The last three Total Current Liabilities figures came in at $11.5 million (Q1 2026), $16.6 million (Q4 2025), and $14.6 million (Q3 2025), per Business Quant data.